DSG3-CAART for anti-DSG3 pemphigus vulgaris

This is a phase 1, open-label study to determine the maximum tolerated dose (MTD) and dose fractionation of autologous T cells expressing desmoglein 3 (DSG3) chimeric autoantibody receptors (CAARs) fused to tandem 4-1BB and CD3ζ signaling domains (collectively referred to as "DSG3-CAART") in the treatment of subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris (PV). This protocol also allows for retreatment of subjects who received DSG3-CAART therapy and subsequently did not achieve complete remission or experienced a disease relapse after achieving complete remission.